Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)
Lebrikizumab 250 mg Q2W combined with TCS significantly improved signs and symptoms of AD at week 16 in adults and adolescents with moderate-to-severe AD and history of inadequate response to CsA or for whom CsA was not medically advisable, and those benefits were maintained and/or further improved by week 52. Safety was consistent with the known lebrikizumab safety profile.
Authors
- Marjolein S. de Bruin-Weller (ORCID: https://orcid.org/0000-0002-1249-6993)
- Athanasios Tsianakas (ORCID: https://orcid.org/0000-0003-1563-7402)
- Hwanhee Hong (ORCID: https://orcid.org/0000-0002-3736-6327)
- Ruth Coll (ORCID: https://orcid.org/0000-0003-0174-379X)
- Jacek Cezary Szepietowski (ORCID: https://orcid.org/0000-0003-0766-6342)
- A. Khemis (ORCID: https://orcid.org/0000-0003-1329-5875)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Stephan Weidinger (ORCID: https://orcid.org/0000-0003-3944-252X)
- Helena Agell
- Èric Massana
- Meritxell Falqués
- Esther Garcia Gil
- Yanislav Mihaylov
Institutions
- Wrocław University of Science and Technology (PL)
- University of British Columbia (CA)
- Manchester Academic Health Science Centre (GB)
- University Medical Center Utrecht (NL)
- Wroclaw Medical University (PL)
- Zentralklinik Bad Berka (DE)
- University Hospital Schleswig-Holstein (DE)
- Almirall (Spain) (ES)
- NIHR Manchester Biomedical Research Centre (GB)
- AGH University of Krakow (PL)
- University of Lübeck (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1093/bjd/ljaf285
- Citations
- 5
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 10.02